Exhalative markers FeNO, PGE2 and 8-isoprostane as diagnostic and prognostic biomarkers in interstitial lung diseases

E Krauss; M Brinkmeier; W Seeger; F Drakopanagiotakis; B Crestani; A Günther

doi:10.1055/s-0039-1678277

Pneumologie, Inhaltsverzeichnis

Pneumologie 2019; 73(S 01)
DOI: 10.1055/s-0039-1678277

Posterbegehung (P22) – Sektion Klinische Pneumologie

Fortschritte bei ILD

Georg Thieme Verlag KG Stuttgart · New York

Exhalative markers FeNO, PGE2 and 8-isoprostane as diagnostic and prognostic biomarkers in interstitial lung diseases

Authors

E Krauss

¹European Ipf Registry & Biobank (Euripfreg), Universities of Gießen and Marburg Lung Center (Ugmlc), Member of the German Center for Lung Research (Dzl), Excellence Cluster Cardiopulmonary System (Eccps), Gießen, Universities of Giessen and Marburg Lung Center
M Brinkmeier

²European Ipf Registry & Biobank (Euripfreg), Universities of Gießen and Marburg Lung Center (Ugmlc), Member of the German Center for Lung Research (Dzl), Giessen, Germany
W Seeger

³Universitätsklinikum Gießen, Zentrum für Innere Medizin, Medizinische Klinik II
F Drakopanagiotakis

⁴European Ipf Registry & Biobank (Euripfreg), Universities of Gießen and Marburg Lung Center (Ugmlc), Member of the German Center for Lung Research (Dzl)
B Crestani

⁵Competence Center for Rare Pulmonary Diseases, Hopital Bichat, Paris, France
A Günther

⁶Univ.-Klinikum Gießen, Med. Klinik II, Schwerpunkt Pneumologie

Abstract

Volltext

Background Non-invasive methods and new biomarkers are urgently needed to improve non-invasive diagnostics in ILD, thus reducing the complex and high-risk interventions for patients and enabling the monitoring of medical treatment. Hence, the significance of exhaled NO and other volatile biomarkers are of great scientific interest.

Methods In this study we investigated, if patients with IPF (n = 36), other ILDs (n = 66) and other lung diseases (COPD n = 24, BC n = 16) as well as healthy subjects (n = 54) show relevant differences of exhaled NO (FeNO) as well the eicosanoids PGE2 and 8-isoprostane in exhaled breath condensate (EBC) and bronchoalveolar lavage (BALF).

Results There was no significant difference in the FeNO measurements of IPF, ILD and healthy subjects, although, some patients showed highly elevated FeNO. In general, it was neither possible to differentiate between the origin of disease, nor to detect exacerbation on basis of FeNO values. The investigation of arachidonic acid derivate in breath condensate was difficult (PGE2) or unreliable (8-isoprostane), but it worked out well in BALF. Group-specific differences were observed only in free 8-isoprostane, which could indicate the severity of oxidative stress.

Conclusions The FeNO-measurement gives no diagnostic benefit for ILDs or IPFs on basis of our results. The same is valid for the measured PGE2 and 8-isoprostane in EBC by ELISA. The differences measured in BALF regarding 8-isoprostane appear insignificant for the clinical use as a non-invasive diagnostic tool.